aidsmap news story
A broadly neutralising antibody from ViiV Healthcare, now named lotivibart, could potentially be paired with cabotegravir injections for long-acting HIV treatment, according to the latest results from the EMBRACE study presented at CROI 2026.
Building on results presented at last year’s CROI, Dr Charlotte-Paige Rolle of the Orlando Immunology Center in Florida reported that most people who switched from a standard oral antiretroviral regimen to lotivibart intravenous infusions or injections every four months plus monthly cabotegravir injections maintained viral suppression at one year. However, she also noted that lotivibart infusions were better tolerated than the injectable formulation.
Read the full news story here.
View all aidsmap reports from CROI 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.